Page last updated: 2024-09-03

deoxyfuconojirimycin and Glycogen Storage Disease Type II

deoxyfuconojirimycin has been researched along with Glycogen Storage Disease Type II in 1 studies

*Glycogen Storage Disease Type II: An autosomal recessively inherited glycogen storage disease caused by GLUCAN 1,4-ALPHA-GLUCOSIDASE deficiency. Large amounts of GLYCOGEN accumulate in the LYSOSOMES of skeletal muscle (MUSCLE, SKELETAL); HEART; LIVER; SPINAL CORD; and BRAIN. Three forms have been described: infantile, childhood, and adult. The infantile form is fatal in infancy and presents with hypotonia and a hypertrophic cardiomyopathy (CARDIOMYOPATHY, HYPERTROPHIC). The childhood form usually presents in the second year of life with proximal weakness and respiratory symptoms. The adult form consists of a slowly progressive proximal myopathy. (From Muscle Nerve 1995;3:S61-9; Menkes, Textbook of Child Neurology, 5th ed, pp73-4) [MeSH]

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Fleet, GWJ; Jia, YM; Kanekiyo, U; Kato, A; Kishida, M; Li, YX; Lu, TT; Nakagome, I; Nash, RJ; Shinzawa, K; Tanaka, N; Yoshida, T; Yoshimura, K; Yu, CY1

Other Studies

1 other study(ies) available for deoxyfuconojirimycin and Glycogen Storage Disease Type II

ArticleYear
5-
    Journal of medicinal chemistry, 2022, 02-10, Volume: 65, Issue:3

    Topics: 1-Deoxynojirimycin; Alkylation; alpha-Glucosidases; Enzyme Inhibitors; Fibroblasts; Glycogen Storage Disease Type II; Humans; Molecular Dynamics Simulation; Molecular Structure; Mutation; Protein Conformation; Protein Stability; Recombinant Proteins

2022